Off-the-shelf CD123 CAR-NK for R/R AML

In this study, doctors are testing a new treatment for a type of blood cancer called acute myeloid leukemia (AML). The treatment involves using special cells called CAR-NK cells, which are taken from a healthy person and designed to target and fight the cancer cells. CAR-NK stands for Chimeric Antigen Receptor Natural Killer cells. Patients will first receive chemotherapy (using drugs Fludarabine and Cyclophosphamide) and then the CAR-NK cells are injected. Researchers want to see how safe the treatment is and if it helps patients with tough-to-treat AML.

• The study requires patients to be 18 years or older and can be any gender or race.
• Participants must have a life expectancy of at least 3 months and be able to understand and sign an informed consent form.
• Those who join can't have certain health issues like active infections or allergies to certain medicines, and they must use contraception if possible.

This study is only happening at one location, so travel might be necessary. Remember, there are risks and benefits, so discussing with your doctor is important!